NASDAQ:DVAX

Dynavax Technologies Competitors

$10.07
0.00 (0.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.58
Now: $10.07
$10.08
50-Day Range
$8.16
MA: $9.53
$10.99
52-Week Range
$2.89
Now: $10.07
$12.44
Volume1.69 million shs
Average Volume5.64 million shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.34

Competitors

Dynavax Technologies (NASDAQ:DVAX) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying DVAX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Dynavax Technologies, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Dynavax Technologies (NASDAQ:DVAX) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Profitability

This table compares Dynavax Technologies and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dynavax Technologies-256.92%-193.85%-23.45%
Amgen29.42%95.55%15.52%

Risk and Volatility

Dynavax Technologies has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Earnings and Valuation

This table compares Dynavax Technologies and Amgen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynavax Technologies$35.22 million32.38$-152,600,000.00($1.87)-5.39
Amgen$23.36 billion6.14$7.84 billion$14.8216.80

Amgen has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 13.3% of Dynavax Technologies shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Dynavax Technologies and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dynavax Technologies00403.00
Amgen0101402.58

Dynavax Technologies currently has a consensus target price of $16.3333, indicating a potential upside of 62.20%. Amgen has a consensus target price of $259.4091, indicating a potential upside of 4.21%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Dynavax Technologies is more favorable than Amgen.

Summary

Amgen beats Dynavax Technologies on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Dynavax Technologies (NASDAQ:DVAX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Gilead Sciences and Dynavax Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191402.54
Dynavax Technologies00403.00

Gilead Sciences currently has a consensus target price of $97.2308, suggesting a potential upside of 50.37%. Dynavax Technologies has a consensus target price of $16.3333, suggesting a potential upside of 62.20%. Given Dynavax Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Dynavax Technologies is more favorable than Gilead Sciences.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 80.0% of Dynavax Technologies shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 13.3% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Dynavax Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Dynavax Technologies-256.92%-193.85%-23.45%

Valuation and Earnings

This table compares Gilead Sciences and Dynavax Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.63$5.39 billion$6.1410.53
Dynavax Technologies$35.22 million32.38$-152,600,000.00($1.87)-5.39

Gilead Sciences has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Dynavax Technologies on 8 of the 14 factors compared between the two stocks.

Dynavax Technologies (NASDAQ:DVAX) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Institutional & Insider Ownership

80.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 13.3% of Dynavax Technologies shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Dynavax Technologies and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dynavax Technologies-256.92%-193.85%-23.45%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Dynavax Technologies and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dynavax Technologies00403.00
Vertex Pharmaceuticals042112.88

Dynavax Technologies presently has a consensus price target of $16.3333, suggesting a potential upside of 62.20%. Vertex Pharmaceuticals has a consensus price target of $293.1250, suggesting a potential upside of 37.23%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe Dynavax Technologies is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Dynavax Technologies has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Dynavax Technologies and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynavax Technologies$35.22 million32.38$-152,600,000.00($1.87)-5.39
Vertex Pharmaceuticals$4.16 billion13.34$1.18 billion$4.2949.79

Vertex Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Dynavax Technologies on 10 of the 15 factors compared between the two stocks.

Dynavax Technologies (NASDAQ:DVAX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Profitability

This table compares Dynavax Technologies and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dynavax Technologies-256.92%-193.85%-23.45%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Risk & Volatility

Dynavax Technologies has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Dynavax Technologies and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dynavax Technologies00403.00
Regeneron Pharmaceuticals051412.80

Dynavax Technologies presently has a consensus target price of $16.3333, suggesting a potential upside of 62.20%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, suggesting a potential upside of 34.77%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Dynavax Technologies is more favorable than Regeneron Pharmaceuticals.

Earnings and Valuation

This table compares Dynavax Technologies and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynavax Technologies$35.22 million32.38$-152,600,000.00($1.87)-5.39
Regeneron Pharmaceuticals$7.86 billion6.44$2.12 billion$21.4722.02

Regeneron Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

80.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 13.3% of Dynavax Technologies shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Dynavax Technologies on 10 of the 15 factors compared between the two stocks.

Dynavax Technologies (NASDAQ:DVAX) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for Dynavax Technologies and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dynavax Technologies00403.00
Biogen5141202.23

Dynavax Technologies currently has a consensus target price of $16.3333, indicating a potential upside of 62.20%. Biogen has a consensus target price of $303.5862, indicating a potential upside of 15.52%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Dynavax Technologies is more favorable than Biogen.

Insider & Institutional Ownership

80.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 13.3% of Dynavax Technologies shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Dynavax Technologies and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynavax Technologies$35.22 million32.38$-152,600,000.00($1.87)-5.39
Biogen$14.38 billion2.78$5.89 billion$33.577.83

Biogen has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Dynavax Technologies has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares Dynavax Technologies and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dynavax Technologies-256.92%-193.85%-23.45%
Biogen35.63%51.00%23.54%

Summary

Biogen beats Dynavax Technologies on 9 of the 14 factors compared between the two stocks.

Dynavax Technologies (NASDAQ:DVAX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Profitability

This table compares Dynavax Technologies and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dynavax Technologies-256.92%-193.85%-23.45%
Alexion Pharmaceuticals16.32%23.16%14.76%

Valuation and Earnings

This table compares Dynavax Technologies and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynavax Technologies$35.22 million32.38$-152,600,000.00($1.87)-5.39
Alexion Pharmaceuticals$4.99 billion6.78$2.40 billion$9.7415.81

Alexion Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Dynavax Technologies and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dynavax Technologies00403.00
Alexion Pharmaceuticals017512.30

Dynavax Technologies currently has a consensus target price of $16.3333, suggesting a potential upside of 62.20%. Alexion Pharmaceuticals has a consensus target price of $153.8636, suggesting a potential downside of 0.10%. Given Dynavax Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Dynavax Technologies is more favorable than Alexion Pharmaceuticals.

Institutional & Insider Ownership

80.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 13.3% of Dynavax Technologies shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Dynavax Technologies has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Dynavax Technologies on 10 of the 15 factors compared between the two stocks.


Dynavax Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.94flat$143.34 billion$23.36 billion20.08
Gilead Sciences logo
GILD
Gilead Sciences
2.8$64.66flat$81.41 billion$22.45 billion66.66
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.60flat$55.53 billion$4.16 billion26.97Analyst Report
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$472.80flat$50.65 billion$7.86 billion17.28News Coverage
Biogen logo
BIIB
Biogen
1.9$262.80flat$40.03 billion$14.38 billion8.70Analyst Report
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$154.01flat$33.86 billion$4.99 billion35.98
Seagen logo
SGEN
Seagen
1.7$140.72flat$25.51 billion$916.71 million55.40Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$124.94flat$21.13 billion$876.29 million-56.53
Incyte logo
INCY
Incyte
1.9$79.87flat$17.56 billion$2.16 billion-50.87
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$135.03flat$15.84 billion$219.75 million-17.25
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.11flat$14.02 billion$1.70 billion17.65
Novavax logo
NVAX
Novavax
1.6$175.65flat$12.97 billion$18.66 million-33.65
Repligen logo
RGEN
Repligen
1.5$207.02flat$11.34 billion$270.24 million252.46Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$198.59flat$8.85 billion$1.45 billion18.79
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.79flat$8.72 billion$788.10 million99.78Analyst Report
Increase in Short Interest
News Coverage
Exelixis logo
EXEL
Exelixis
1.9$23.03flat$7.19 billion$967.78 million47.98
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.95flat$6.15 billion$195.99 million268.44
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.87flat$5.76 billion$1.12 billion85.15
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86flat$4.04 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76flat$3.91 billion$806.43 million-9.17
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31flat$3.23 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.4$18.78flat$2.99 billion$1.17 billion-40.83
OPKO Health logo
OPK
OPKO Health
1.9$4.06flat$2.72 billion$901.90 million-22.55
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29flat$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90flat$2.41 billion$120.28 million-146.36Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.46flat$2.07 billion$638.60 million-10.56
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02flat$1.88 billionN/A-10.57
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$9.50flat$1.69 billion$48.83 million-12.50
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.16flat$1.64 billion$428.41 million14.72
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.06flat$1.59 billion$102.43 million-18.43Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$23.47flat$1.51 billion$68.46 million-67.06Analyst Report
News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.18flat$1.43 billion$82.27 million-17.51
Innoviva logo
INVA
Innoviva
1.4$11.67flat$1.18 billion$261.02 million5.95
MannKind logo
MNKD
MannKind
1.4$4.18flat$1.04 billion$63.04 million-19.90Increase in Short Interest
Curis logo
CRIS
Curis
1.3$10.82flat$990.24 million$10 million-13.20Increase in Short Interest
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$15.92flat$873.74 million$227.19 million44.22Analyst Downgrade
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$20.79flat$823.60 million$3.57 million-9.32
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$21.84flat$793.40 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.07flat$731.88 million$322.07 million-4.83Decrease in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.14flat$730.97 million$252 million-2.26
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.26flat$701.57 million$150,000.00-4.66Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.16flat$643.91 million$143.01 million-1.18
Agenus logo
AGEN
Agenus
1.6$2.68flat$547.53 million$150.05 million-2.45
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.09flat$525.67 million$59.29 million-20.60Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.48flat$520.09 million$36.63 million-6.45News Coverage
Gap Down
Geron logo
GERN
Geron
1.4$1.42flat$452.31 million$460,000.00-4.06Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.94flat$451.96 million$109.33 million-2.16Analyst Report
News Coverage
Verastem logo
VSTM
Verastem
1.3$2.57flat$441.18 million$17.46 million-1.82Analyst Revision
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.82flat$438.33 million$22.27 million-3.83
XOMA logo
XOMA
XOMA
1.3$37.98flat$427.39 million$18.37 million-34.22Increase in Short Interest
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.